Trial site
Carolina Biooncology Institute
- 9running trials
- 14closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Conditions
- Lung cancer12 trials
- Ovarian cancer9 trials
- Pancreatic cancer9 trials
- Gastric and oesophageal cancer8 trials
- Colorectal cancer7 trials
- Head and neck cancer6 trials
- Bladder cancer5 trials
- Prostate cancer5 trials
- Cervical cancer4 trials
- Triple-negative breast cancer4 trials
- Endometrial cancer3 trials
- Kidney cancer3 trials
- and 5 more
- Phase
- Phase 1/212 trials
- Phase 110 trials
- Status
- Completed8 trials
- Recruiting8 trials
- Terminated5 trials
- Active, not recruiting1 trial
- Withdrawn1 trial
- Lead sponsor
- Conjupro Biotherapeutics, Inc.2 trials
- Nuvation Bio Inc.2 trials
- AbbVie1 trial
- Apollo Therapeutics Ltd1 trial
- Aulos Bioscience, Inc.1 trial
- and 16 more
Running trials
Recruiting
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Active, not recruiting
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer5 recruiting
- Bladder cancer3 recruiting
- Colorectal cancer3 recruiting
- Pancreatic cancer3 recruiting
- Cervical cancer2 recruiting
- Gastric and oesophageal cancer2 recruiting
- Head and neck cancer2 recruiting
- Kidney cancer2 recruiting
- Melanoma2 recruiting
- Childhood cancers1 recruiting
- Endometrial cancer1 recruiting
- Liver and biliary tract cancer1 recruiting
- Metastatic breast cancer1 recruiting
- Ovarian cancer1 recruiting
Closed trials
Recruiting
Recruiting
Completed
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Terminated
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
Terminated
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Recruiting
Completed
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Terminated
Terminated
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Terminated
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Completed
Completed
Completed
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Site data: ClinicalTrials.govUpdated 12 Nov 2026